Human Herpesvirus 8
Conditions
Brief summary
The purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of HHV-8 shedding in HHV-8 seropositive men. Our hypothesis is that valganciclovir will substantially reduce the frequency of detection and amount of HHV-8 in the mouth.
Detailed description
The purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of HHV-8 shedding in HHV-8 seropositive men. Our hypothesis is that valganciclovir will substantially reduce the frequency of detection and amount of HHV-8 in the mouth. Such reduction will serve to confirm that the mouth is the site of active HHV-8 replication. If valganciclovir is found to be effective, the findings from this proposal would serve as the basis for a clinical trial with valganciclovir for prevention of Kaposi's Sarcoma (KS) in high-risk HHV-8 seropositive persons. After informed consent, all subjects will undergo medical history, physical examination and screening laboratory examination. Eligible patients will return to clinic for randomization to receiver either valganciclovir 900 mg qd or placebo. Participants will receive a diary for noting adverse events and concurrent medications. The clinician will instruct the participants on collection of mouth swabs and provide Dacron swabs, vials with PCR media and pre-printed labels. Subjects will be asked to obtain a swab of oral mucosa every morning. Clinic visits every other week will serve to review interim medical history and diaries for adverse events, collect PCR swabs, dispense additional medication and draw safety labs. The study uses a double-blind, randomized placebo design. Therefore, participants will not know whether they will be taking a placebo or active medication at any time during the study. Due to the crossover study design, however, all participants will receive the same amount of placebo and study drug over the duration.
Interventions
DRUGvalganciclovir
900 mg once a day for 8 weeks
DRUGplacebo
matching placebo, once a day for 8 weeks
Sponsors
Hoffmann-La Roche
University of Washington
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or older * HHV-8 seropositive or previous evidence of HHV-8 shedding * a frequent shedder of HHV-8 * not receiving any drugs with known anti-HHV-8 activity for study duration * able to comply with the study protocol * agree to HIV testing
Exclusion criteria
* history of evidence of CMV disease * hypersensitivity to ganciclovir or valganciclovir * use of high-dose acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, or cidofovir * neutropenia * renal insufficiency with serum creatinine greater than 1.5mg.ml or CrCl less than 60 * AST or ALT greater than 5 times upper limit of normal * concurrent administration of medications which are often associated with severe neutropenia or thrombocytopenia * concurrent administration of probenecid or didanosine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The reduction in percent days on which HHV-8 is detected on versus off valganciclovir. The quantitative reduction in the HHV-8 DNA detected by PCR on versus off valganciclovir. | 19 weeks |
Secondary
| Measure | Time frame |
|---|---|
| The frequency of neutropenia, defined as ANC less than 500. The frequency of thrombocytopenia, defined as platelets less than 75,000. | 19 weeks |
Countries
United States
Outcome results
None listed